All In Biotech

NDA 021038 · Hospira

Precedex

Dexmedetomidine Hydrochloride · Injection

Novel

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Dec 17, 1999

Approved uses

5

Original approval plus efficacy supplements

Registered trials

1,922

279 Phase 3, 159 recruiting

FAERS reports

2,999

2,792 serious, 459 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 17, 2026.

PRECEDEX is a alpha 2 -adrenergic receptor agonist indicated for: • Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer PRECEDEX by continuous infusion not to exceed 24 hours. ( 1.1 ) • Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. ( 1.2 ) • Sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures. ( 1.2 ) 1.1 Intensive Care Unit Sedation PRECEDEX is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. PRECEDEX should be administered by continuous infusion not to exceed 24 hours. PRECEDEX has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue PRECEDEX prior to extubation. 1.2 Procedural Sedation PRECEDEX is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. PRECEDEX is indicated for sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures.

Mechanism: PRECEDEX is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10-300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid intravenous administration.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 1MG BASE/250ML (EQ 4MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexmedetomidine" as an intervention, any sponsor and status, largest first.

All 1,922 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bradycardia258
  • off label use238
  • hypotension181
  • cardiac arrest172
  • pyrexia116
  • drug ineffective107
  • product use in unapproved indication101
  • pneumonia100
  • product use issue92
  • drug interaction86
  • oxygen saturation decreased86
  • respiratory failure86

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
200510
200627
200721
200829
200934
201048
201159
201272
201386
201498
2015104
2016212
2017188
2018192
2019238
2020233
2021207
2022229
2023270
2024246
2025258
2026129

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 6, 2026

    Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24).

  • Current · updated Nov 6, 2026

    Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24).

  • Current · updated Nov 6, 2026

    Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20).

  • Current · updated Nov 6, 2026

    Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50).

  • Current · updated Nov 6, 2026

    Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20).

  • Current · updated Nov 6, 2026

    Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,906 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.